Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Update

22 Jul 2021 07:00

RNS Number : 0521G
Xaar PLC
22 July 2021
 

 

 

Xaar plc

 

Trading Update

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology group, today announces a trading update for the six months ended 30 June 2021.

 

TRADING

 

The Board is pleased to announce that trading for the six months ended 30 June 2021 has been in line with its expectations. Revenue for the period is expected to be approximately £26 million, representing an increase of 11% and 8% relative to H1 and H2 2020 respectively.

 

The Printhead business continues to perform well following the ongoing successful roll out of the ImagineX platform and launch of the Xaar Nitrox printhead in April, which is attracting new customers and increased opportunities to broaden the offering in applications where our products are market leading. Whilst we are seeing some COVID-19 related supply constraints, we are taking the required actions to mitigate their impact and continue to be optimistic on the future trading environment.

 

Revenues for the Product Print Systems business (EPS) are in line with management expectations, being below that achieved in H1 2020. Whilst the underlying performance remains on track and the business continues to be profitable, H1 2021 results have been impacted by non-cash adjustments relating to slow moving and obsolete inventory following the implementation of planned process improvement and strategy actions announced at our full year results.

 

Negotiations to divest Xaar's interest in Xaar 3D are now at an advanced stage and a further update will be announced to shareholders in due course.

 

BALANCE SHEET AND LIQUIDITY

 

The Group retains a strong balance sheet and cash position. Net cash at 30 June 2021, excluding cash from the 3D business (which is classified as an asset held for sale) was £17.1 million. This represents a decline of £1.0 million in net cash for continuing operations since 31 December 2020, which has been primarily driven by planned capital investment, including the relocation of Xaar's Cambridge office which will generate £0.7 million of annual cost savings. The Group maintains a strong cash focus and disciplined cost controls.

 

TRADING OUTLOOK

 

Whilst the COVID-19 pandemic continues to have a wider economic impact, our short-term outlook remains positive with a healthy order book across the business. We continue to focus on implementing our strategy to enable future growth and remain on-track to return to profitability in the medium term.

 

We announced on 12 July 2021 the acquisition of FFEI Limited ("FFEI"), a leading integrator and manufacturer of industrial digital inkjet systems and digital life science technology. The addition of FFEI strengthens Xaar's capabilities and skills and will accelerate Xaar's existing growth strategy. 

 

 

John Mills, Chief Executive Officer, commented:

 

"We are pleased with our continued good performance which shows the positive momentum we have in the business. Our strong foundations remain, and we continue to gain new customers and see positive re-engagement with the business as our strategy is proving to work. We are investing in capability and capacity to drive future growth and the addition of FFEI to the Group will provide us with further opportunities to grow the business and accelerate our strategy."

 

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

 

John Mills, Chief Executive Officer

 

 

Tulchan Communications

James Macey White

Giles Kernick

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKDBKFBKDOOB
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.